Equity Analysis: Watson Pharma, Coinstar, HCA, FedEx, Express Scripts

Watson Pharmaceuticals Inc.(NYSE:WPI): Leerink says day one of the Lidoderm patent trial produced no surprises, adding it continues to expect Watson Pharmaceuticals (NYSE:WPI) to prevail. The firm found testimony from Endo Pharmaceuticals’ (NASDAQ:ENDP) witnesses to be credible, but not relevant to the primary issue of infringement.

Coinstar Inc.(NASDAQ:CSTR): Benchmark Co. raised its estimates and price target for Coinstar citing the company’s better than expected Q4 results and acquisition of NCR’s entertainment line of business. The firm maintains a Buy rating on the stock.

HCA Holdings Inc(NYSE:HCA): HCA Holdings removed from short-term buy list at Deutsche Bank

FedEx Corporation(NYSE:FDX): FedEx removed from short-term buy list at Deutsche Bank

Express Scripts Inc.(NASDAQ:ESRX): William Blair continues to believe the Express Scripts (NASDAQ:ESRX), Medco Health (NYSE:MHS) merger is likely to eventually close, but thinks remedies such as the divestiture of certain specialty or mail]order assets are likely. The firm maintains an Outperform rating on Express Scripts and a Market Perform rating on Medco.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com